Tags : Polatuzumab Vedotin

Roche’s Polivy (polatuzumab vedotin) Based Combination Regimen Receives EC’s Approval

Tuba Khan January 21, 2020

Shots: The conditional approval is based on P-Ib/II GO29365 study assessing Polivy + bendamustine and MabThera (rituximab) (BR) or Gazyvaro (obinutuzumab) vs BR in R/R FL or DLBCL patients who […]readmore

Regulatory

Roche’s Polatuzumab Vedotin as Combination Therapy & Entrectinib Receives FDA’s

Vartika Singh February 19, 2019

Shots: The FDA’s PR designation to the combination of Polatuzumab Vedotin + bendamustine (B)+ Rituxan (rituximab, R) vs BR as monothx & Entrectinib are based on GO29365 & STARTRK (1,2, […]readmore

Tags : Polatuzumab Vedotin

Roche’s Polivy (polatuzumab vedotin) Based Combination Regimen Receives EC’s Approval

Roche’s Polatuzumab Vedotin as Combination Therapy & Entrectinib Receives FDA’s

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Company

Tags : Polatuzumab Vedotin

Roche’s Polivy (polatuzumab vedotin) Based Combination Regimen Receives EC’s Approval

Roche’s Polatuzumab Vedotin as Combination Therapy & Entrectinib Receives FDA’s

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Categories

Related Topics

Company